uniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for ifezuntirgene inilparvovec for the Treatment of Huntington’s Disease

~ FDA sets PDUFA target action date of May 1, 2027 ~~ If approved, ifezuntirgene inilparvovec will be the world’s first disease-modifying...

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (markets.businessinsider.com)